ISR Articles
-
Customer Loyalty In Biologic Drug Product Manufacturing
5/15/2019
ISR surveyed sponsors who outsource drug substance manufacturing for biologic compounds to gain insight into their CMO loyalty. ISR computes customer loyalty as an index that consists of overall satisfaction, willingness to recommend, and likelihood to use the CMO again.
-
Biologic Drug Substance And Drug Product Preferred Provider Use
4/15/2019
ISR data shows the majority of those who outsource biologic drug substance and drug product use a preferred provider approach to outsourcing, and average about four CMOs on their lists.
-
Standing Out In The Crowded Biopharma CDMO Market
3/14/2019
This presentation addresses what motivates drug innovators to outsource, who is involved in service provider selection, and which attributes have the greatest influence on CDMO selection.
-
How Do Experience And Capacity Impact Oral Dose Outsourcing?
2/25/2019
In Q2 2018, ISR asked 44 outsourcers of oral solid dose drug product manufacturing to select from four different reasons that manufacturing may be split between in-house and external resources.
-
Outsourcing Drivers By Company Size
2/25/2019
In Q4 2018, ISR surveyed 121 outsourcers of large molecule drug substance manufacturing to understand their primary reason for working with CMOs for biologic API. The data show respondents from small companies, with an annual R&D spend under $1B, are more likely to use CMOs for all of their manufacturing needs than respondents from large pharma companies (61% vs 24%).
-
Most Difficult Aspects Of Biosimilar Manufacturing
1/14/2019
Research firm ISR asked 109 respondents who are responsible for outsourcing biologic API to hypothesize what would be the most difficult aspect of manufacturing a biosimilar.
-
Outsourcing Impact Of Focus On Innovative Treatment
11/15/2018
In Q4, 2017, ISR asked a follow-up question to respondents who agreed that their company’s focus on developing new innovative treatments will impact its outsourcing practices.
-
Change Of Focus For Biopharma Manufacturers
11/15/2018
In Q4, 2017, ISR asked 730 buyers of outsourced manufacturing services about upcoming changes to their pipeline and how it might impact their outsourcing practices.
-
What Will Drive Biologics Market Growth?
8/8/2018
In Q2,2018, ISR surveyed drug innovators who outsource bioprocessing/biologic API manufacturing to learn their thoughts on what will have the greatest impact on market growth over the next five years.
-
Benefits Of Using Preferred Providers For Clinical Development Outsourcing
5/22/2018
Results from a Q1 2018 ISR survey of 117 outsourcers at biopharmaceutical sponsors regarding the use and performance of a variety of clinical development outsourcing models.